511 related articles for article (PubMed ID: 30264512)
1. Tofacitinib for the treatment of lichen planopilaris: A case series.
Yang CC; Khanna T; Sallee B; Christiano AM; Bordone LA
Dermatol Ther; 2018 Nov; 31(6):e12656. PubMed ID: 30264512
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study.
Shin JW; Huh CH; Kim MW; Lee JS; Kwon O; Cho S; Park HS
Acta Derm Venereol; 2019 Jan; 99(1):41-46. PubMed ID: 30281139
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system.
Chiang C; Sah D; Cho BK; Ochoa BE; Price VH
J Am Acad Dermatol; 2010 Mar; 62(3):387-92. PubMed ID: 20061052
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.
Kossard S; Lee MS; Wilkinson B
J Am Acad Dermatol; 1997 Jan; 36(1):59-66. PubMed ID: 8996262
[TBL] [Abstract][Full Text] [Related]
5. Diffuse variants of scalp lichen planopilaris: Clinical, trichoscopic, and histopathologic features of 40 patients.
Starace M; Orlando G; Alessandrini A; Baraldi C; Bruni F; Piraccini BM
J Am Acad Dermatol; 2020 Dec; 83(6):1659-1667. PubMed ID: 31706933
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
7. Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab.
Trindade de Carvalho L; Meah N; Wall D; Sinclair R
Dermatol Ther; 2020 Jul; 33(4):e13694. PubMed ID: 32458516
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib as Treatment for Nail Lichen Planus Associated With Alopecia Universalis.
Iorizzo M; Haneke E
JAMA Dermatol; 2021 Mar; 157(3):352-353. PubMed ID: 33404596
[No Abstract] [Full Text] [Related]
9. A case series of 46 patients with lichen planopilaris: Demographics, clinical evaluation, and treatment experience.
Lyakhovitsky A; Amichai B; Sizopoulou C; Barzilai A
J Dermatolog Treat; 2015 Jun; 26(3):275-9. PubMed ID: 24913130
[TBL] [Abstract][Full Text] [Related]
10. Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.
Fechine COC; Valente NYS; Romiti R
An Bras Dermatol; 2022; 97(3):348-357. PubMed ID: 35379508
[TBL] [Abstract][Full Text] [Related]
11. Response of alopecia areata of the beard to oral tofacitinib.
Kerkemeyer KLS; John JM; Sinclair R; Bhoyrul B
J Am Acad Dermatol; 2020 May; 82(5):1228-1230. PubMed ID: 31678329
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of mycophenolate mofetil for lichen planopilaris.
Cho BK; Sah D; Chwalek J; Roseborough I; Ochoa B; Chiang C; Price VH
J Am Acad Dermatol; 2010 Mar; 62(3):393-7. PubMed ID: 20061053
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
14. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
[TBL] [Abstract][Full Text] [Related]
16. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
17. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Huang F; Luo ZC
Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
[TBL] [Abstract][Full Text] [Related]
18. Lichen planus pigmentosus and lichen planopilaris.
Cobos G; Kim RH; Meehan S; Elbuluk N
Dermatol Online J; 2016 Dec; 22(12):. PubMed ID: 28329547
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
